LOS ANGELES / Aug 07, 2023 / Business Wire / ChromaDex Corp. (NASDAQ:CDXC), a global authority on Nicotinamide Adenine Dinucleotide (NAD+) research and healthy aging, announced today that they will be participating in Renmark Financial Communications Inc.’s live Virtual Non-Deal Roadshow Series to discuss its latest investor presentation on Monday, August 14, 2023, at 12:00 p.m. ET (9:00 a.m. PT) and Wednesday, August 16, 2023 at 2:00 p.m. ET (11:00 a.m. PT). ChromaDex welcomes stakeholders, investors, and other individual followers to register and attend these live events.
The presentations will feature Rob Fried, Chief Executive Officer, and Brianna Gerber, Chief Financial Officer. Topics to be covered will include the latest investor presentation followed by a live Q&A. Investors interested in participating in either of these events will need to register using the links below. As a reminder, registration for the live events may be limited but access to the replay after the events will be on the company’s Investor website. Investors may submit questions during the presentations or may email questions to This email address is being protected from spambots. You need JavaScript enabled to view it. or This email address is being protected from spambots. You need JavaScript enabled to view it. ahead of the event.
REGISTER HERE:
Monday, August 14, 2023: https://www.renmarkfinancial.com/live-registration/renmark-virtual-non-deal-roadshow-nasdaq-cdxc-2023-08-14-120000
Wednesday, August 16, 2023: https://www.renmarkfinancial.com/live-registration/renmark-virtual-non-deal-roadshow-nasdaq-cdxc-2023-08-16-140000
About ChromaDex
ChromaDex Corp. is a global bioscience company dedicated to healthy aging. The ChromaDex team, which includes world-renowned scientists, is pioneering research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age. ChromaDex is the innovator behind NAD+ precursor nicotinamide riboside (NR), commercialized as the flagship ingredient Niagen®. Nicotinamide riboside and other NAD+ precursors are protected by ChromaDex’s patent portfolio. ChromaDex maintains a website at www.chromadex.com to which ChromaDex regularly posts copies of its press releases as well as additional and financial information about the Company.
| Last Trade: | US$7.83 |
| Daily Volume: | 0 |
| Market Cap: | US$598.060M |
June 04, 2025 May 05, 2025 | |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
